February 2, 2016Open Access

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Key Points

Key points are not available for this paper at this time.

Abstract

In this phase 2 study of anemia therapy in patients with end-stage renal disease on maintenance hemodialysis therapy, roxadustat was well tolerated and effectively maintained Hb levels.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Provenzano et al. (Tue,) studied this question.

synapsesocial.com/papers/69d774e3b843b2be9948fdaa https://doi.org/https://doi.org/10.1053/j.ajkd.2015.12.020

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Serum erythropoietin in humans at high altitude and its relation to plasma renin1985 · 161 citations
2US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States2015 · 666 citations
3Role of the hypoxia inducible factors HIF in iron metabolism2008 · 216 citations
4Regulation of Iron Metabolism by Hepcidin2006 · 751 citations
5Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease1992 · 140 citations

Bookmark

View Full Paper